Sep 2026· Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease· pp.
e049040
· 0 citations· 25 references
Medicine
Abstract
Background
The prognostic significance of right heart remodeling (RHR) in patients with secondary tricuspid regurgitation (STR) who do not meet guideline-based indications for tricuspid valve surgery remains uncertain. We evaluated whether advanced markers of RHR are associated with outcomes in medically managed patients with significant STR.
Methods
We retrospectively included 755 patients with significant STR (age 75±12 years). Patients were stratified into 3 groups: Group 1, no current surgical indication (n=519); Group 2, meeting Class I/IIa guideline criteria (n=144); and Group 3, deemed inoperable (n=92). RHR markers included right atrial volume index, right ventricular end-diastolic volume index, forward stroke volume/right ventricular end-systolic volume ratio, and effective right ventricular ejection fraction. The primary end point was a composite of all-cause mortality or heart failure hospitalization.
Results
Group 1 patients had less severe STR and less advanced right ventricular remodeling than Groups 2 and 3. Over a median follow-up of 24 months (interquartile range, 11-34), 330 primary events occurred; 64 patients underwent tricuspid valve intervention. In Group 1, 30-month event-free survival was 71±4% with no RHR markers, 65±3% with 1 or 2 markers, and 33±9% with ≥3 markers (adjusted hazard ratio [aHR], 2.76 [95% CI, 1.74-4.37]; P<0.001). Patients in Group 1 with ≥3 RHR markers had event rates comparable to Group 2 (aHR, 2.79 [95% CI, 1.94-4.02]; P<0.001) and Group 3 (aHR, 4.08 [95% CI, 2.73-6.09]; P<0.001).
Conclusions
Among patients with significant STR without surgical indications, ≥3 markers of RHR identify a high-risk phenotype with outcomes similar to those meeting surgical criteria or considered inoperable.
The TVARC and ASE cutoffs for RV dysfunction showed prognostic value in patients with significant STR, and combining TAPSE and RVFWLS may provide a pragmatic, exploratory framework for risk stratification of these patients.
X. Galloo, M. Dietz, E. Prihadi et al.· JACC Cardiovascular Imaging· 1 citation
BACKGROUND
The effect of transcatheter tricuspid-valve repair on clinical outcomes, including death and hospitalization for heart failure, in patients with severe tricuspid regurgitation remains uncertain.
METHODS
We randomly assigned patients with symptomatic severe tricuspid regurgitation and an increased risk of f...
J. Hausleiter, T. Stocker, Tobias Geisler et al.· New England Journal of Medic...· 6 citations· ⚡1
BACKGROUND
Accurate assessment of right ventricular (RV) performance is crucial in patients with severe tricuspid regurgitation (TR). Conventional RV ejection fraction (RVEF) may overestimate RV systolic function because it does not account for regurgitant volume in severe TR. This study aimed to evaluate the prognosti...
R. Hinojar, C. Fernández-Golfín, J. Palomares et al.· International Journal of Car...· 0 citations
AVR was associated with substantial reverse remodeling at 7 months, including regression of hypertrophy and a fall in indexed extracellular volume volume; the extracellular volume fraction rose, as cellular regression outpaced matrix regression.
George D. Thornton, J. Bennett, N. Aziminia et al.· JAMA cardiology· 0 citations
The CLASP II TR trial will inform the safety and effectiveness of the PASCAL system compared to medical therapy alone in the treatment of patients with symptomatic, severe tricuspid regurgitation.
G. Ailawadi, Charles J. Davidson, Allen S. Anderson et al.· American Heart Journal· 0 citations
Atrial functional tricuspid regurgitation (AFTR) is increasingly recognized as a result of atrial remodelling in patients with atrial fibrillation (AF). However, prognostic predictors in this population remain incompletely defined. To evaluate echocardiographic characteristics and identify predictors of all-cause morta...
Jawza Aldakhil, Kush P. Patel, S. Badiani et al.· Echo Research and Practice· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.